Cargando…
Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data
The economic evaluation of healthcare interventions requires an assessment of whether the improvement in health outcomes they offer exceeds the improvement in health that would have been possible if the additional resources required had, instead, been made available for other healthcare activities....
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231096/ https://www.ncbi.nlm.nih.gov/pubmed/30483412 http://dx.doi.org/10.1136/bmjgh-2018-000964 |
_version_ | 1783370167361732608 |
---|---|
author | Ochalek, Jessica Lomas, James Claxton, Karl |
author_facet | Ochalek, Jessica Lomas, James Claxton, Karl |
author_sort | Ochalek, Jessica |
collection | PubMed |
description | The economic evaluation of healthcare interventions requires an assessment of whether the improvement in health outcomes they offer exceeds the improvement in health that would have been possible if the additional resources required had, instead, been made available for other healthcare activities. Therefore, some assessment of these health opportunity costs is required if the best use is to be made of the resources available for healthcare. This paper provides a framework for generating country-specific estimates of cost per disability-adjusted life year (DALY) averted ‘thresholds’ that reflect health opportunity costs. We apply estimated elasticities on mortality, survival, morbidity and a generic measure of health, DALYs, that take account of measures of a country’s infrastructure and changes in donor funding to country-specific data on health expenditure, epidemiology and demographics to determine the likely DALYs averted from a 1% change in expenditure on health. The resulting range of cost per DALY averted ‘threshold’ estimates for each country that represent likely health opportunity costs tend to fall below the range previously suggested by WHO of 1–3× gross domestic product (GDP) per capita. The 1–3× GDP range and many other previous and existing recommendations about which interventions are cost-effective are not based on an empirical assessment of the likely health opportunity costs, and as a consequence, the health effects of changes in health expenditure have tended to be underestimated, and there is a risk that interventions regarded as cost-effective reduce rather than improve health outcomes overall. |
format | Online Article Text |
id | pubmed-6231096 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-62310962018-11-27 Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data Ochalek, Jessica Lomas, James Claxton, Karl BMJ Glob Health Research The economic evaluation of healthcare interventions requires an assessment of whether the improvement in health outcomes they offer exceeds the improvement in health that would have been possible if the additional resources required had, instead, been made available for other healthcare activities. Therefore, some assessment of these health opportunity costs is required if the best use is to be made of the resources available for healthcare. This paper provides a framework for generating country-specific estimates of cost per disability-adjusted life year (DALY) averted ‘thresholds’ that reflect health opportunity costs. We apply estimated elasticities on mortality, survival, morbidity and a generic measure of health, DALYs, that take account of measures of a country’s infrastructure and changes in donor funding to country-specific data on health expenditure, epidemiology and demographics to determine the likely DALYs averted from a 1% change in expenditure on health. The resulting range of cost per DALY averted ‘threshold’ estimates for each country that represent likely health opportunity costs tend to fall below the range previously suggested by WHO of 1–3× gross domestic product (GDP) per capita. The 1–3× GDP range and many other previous and existing recommendations about which interventions are cost-effective are not based on an empirical assessment of the likely health opportunity costs, and as a consequence, the health effects of changes in health expenditure have tended to be underestimated, and there is a risk that interventions regarded as cost-effective reduce rather than improve health outcomes overall. BMJ Publishing Group 2018-11-05 /pmc/articles/PMC6231096/ /pubmed/30483412 http://dx.doi.org/10.1136/bmjgh-2018-000964 Text en © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0 |
spellingShingle | Research Ochalek, Jessica Lomas, James Claxton, Karl Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data |
title | Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data |
title_full | Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data |
title_fullStr | Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data |
title_full_unstemmed | Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data |
title_short | Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data |
title_sort | estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231096/ https://www.ncbi.nlm.nih.gov/pubmed/30483412 http://dx.doi.org/10.1136/bmjgh-2018-000964 |
work_keys_str_mv | AT ochalekjessica estimatinghealthopportunitycostsinlowincomeandmiddleincomecountriesanovelapproachandevidencefromcrosscountrydata AT lomasjames estimatinghealthopportunitycostsinlowincomeandmiddleincomecountriesanovelapproachandevidencefromcrosscountrydata AT claxtonkarl estimatinghealthopportunitycostsinlowincomeandmiddleincomecountriesanovelapproachandevidencefromcrosscountrydata |